No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 20.6x · 10Y median 14.8x · 94th percentile · as of Oct 6, 2026
Annual revenue · last 3 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:07:02.579Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Heartflow, Inc. Common Stock (HTFL) stock was $50.74 as of Oct 6, 2026, 11:05 AM EDT, down 2.82% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +38.5%
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease.
Medical - Healthcare Information Services · San Francisco, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.10
Revenue Est.
$65.26M
Last Quarter Results
EPS
$-0.07
vs Estimate
$-0.13
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1HTFL | $4.38B | $50.74 | -2.82% | +38.49% | N/A | N/A | N/A |
| 2EWTX | $4.35B | $40.40 | +0.25% | +156.35% | +16.95% | N/A | vs HTFL |
| 3INDV | $4.41B | $35.33 | -1.83% | +55.00% | +19.65% | +6.16% | vs HTFL |
| 4ADPT | $4.43B | $27.68 | -7.26% | +106.79% | -1.77% | N/A | vs HTFL |
| 5LIVN | $4.13B | $75.11 | -1.73% | +42.96% | -1.66% | +2.48% | vs HTFL |
| 6BLLN | $4.64B | $100.88 | -7.50% | N/A | N/A | N/A | vs HTFL |
forward FY estimate
N/A
$64.08M
vs Estimate
$56.64M
Consensus Rating
Based on 9 analysts
Average Price Target
$46.00
-9.3% downside
Low
$39.00
Current
$50.74
High
$56.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.12 | $-0.10 | $-0.08 | 7 |
| Quarter ending Dec 2026 | $-0.11 | $-0.09 | $-0.08 | 7 |
| Quarter ending Mar 2027 | $-0.08 | $-0.08 | $-0.08 | 2 |
| Quarter ending Jun 2027 | $-0.06 | $-0.06 | $-0.06 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.45 | $-0.41 | $-0.38 | 6 |
| FY 2027 | $-0.47 | $-0.26 | $-0.15 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $64.97M | $65.26M | $65.74M | 7 |
| Quarter ending Dec 2026 | $66.16M | $66.80M | $68.03M | 7 |
| Quarter ending Mar 2027 | $70.84M | $71.62M | $73.21M | 3 |
| Quarter ending Jun 2027 | $76.61M | $77.45M | $79.16M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $248.11M | $248.93M | $250.58M | 8 |
| FY 2027 | $300.83M | $309.02M | $314.13M | 8 |
